Executive Vice President, Global Head of Business Development, BeiGene
Dr. Ji Li has more than 20 years of business development and R&D experience in the biopharmaceutical industry. He is currently Executive VP and Global Head of Business Development at BeiGene where he oversees the company’s partnering activities worldwide, including leading the recently completed landmark strategic transaction with Celgene. Prior to BeiGene, Dr. Li served as VP of Business Development and Licensing at Merck, where he led the group that was responsible for BD activities of all late-stage inbound and outbound opportunities globally. Prior to Merck, Dr. Li was Executive Licensing Director, External R&D at Amgen where he led the company’s product search and evaluation BD team. Earlier in his career, Dr. Li was key member of the Amgen research team discovered and validated the RANKL signaling pathway that has led to the successful development and commercialization of Denosumab. Dr. Li obtained his B.S. in Pharmacology from Shanghai Medical University and Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York.